Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547329 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29398074 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29552281 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29400538 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL30695566 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL119866 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29398455 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL119859 | 1.00 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8656057 | 0.90 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL14029674 | 0.89 | MDM4 (0.48) | MDM4TP53CASP3MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727655-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727654-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727653-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250049970-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-02-13 | — | — | US | disclosed |
| US-20250034210-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20250011368-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-01-09 | — | — | US | disclosed |
| WO-2024259115-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024259147-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024259132-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| US-10633419-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
| US-9856292-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3218392-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077518-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160137696-A1 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-19 | — | — | US | disclosed |
| WO-2013071039-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS (US) | 2013-05-16 | — | — | WO | disclosed |
| US-7972992-B2 | Solid phase synthesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100261639-A1 | TRIAZOLE-BASED AMINOGLYCOSIDE-PEPTIDE CONJUGATES AND METHODS OF USE | UNIVERSITY OF MANITOBA (CA) | 2010-10-14 | — | — | US | disclosed |
| WO-2010081882-A2 | SYNTHESIS OF NEW PROTECTED AZAHISTIDINES, THEIR PROCESSES AND THEIR USE IN SYNTHESISES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137696-A1 | Immunomodulators | CD74, ICOS, HAVCR2 | MDM4 672/4885TP53 75/4885CASP3 3617/4885 |
| US-20100261639-A1 | TRIAZOLE-BASED AMINOGLYCOSIDE-PEPTIDE CONJUGATES AND METHODS OF USE | NRDC, ANPEP, DNPEP | MDM4 2185/4885TP53 3202/4885CASP3 1225/4885 |
| US-10633419-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | MDM4 672/4885TP53 75/4885CASP3 3617/4885 |
| US-20180086793-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | MDM4 672/4885TP53 75/4885CASP3 3617/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | MDM4 1294/4885TP53 178/4885CASP3 3268/4885 |
| US-20250049970-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDLIM5 | MDM4 780/4885TP53 109/4885CASP3 2196/4885 |
| US-20250011368-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDCD1LG2 | MDM4 770/4885TP53 134/4885CASP3 2660/4885 |
| US-20250034210-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDCD1LG2 | MDM4 770/4885TP53 134/4885CASP3 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.